Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
259 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Head And Neck Cancer Squamous Cell Carcinoma Overview 9 Therapeutics Development 10 Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 10 Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 11 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 12 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 16 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 21 Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 24 Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 25 Bristol-Myers Squibb Company 25 Boehringer Ingelheim GmbH 26 F. Hoffmann-La Roche Ltd. 27 Shionogi & Co., Ltd. 28 Amgen Inc. 29 Eli Lilly and Company 30 GlaxoSmithKline plc 31 Celltrion, Inc. 32 Novartis AG 33 Eisai Co., Ltd. 34 ImmunoGen, Inc. 35 Santaris Pharma A/S 36 CEL-SCI Corporation 37 OXiGENE, Inc. 38 Takara Bio Inc. 39 Panacea Biotec Limited 40 PCI Biotech AS 41 Nanobiotix 42 Acceleron Pharma, Inc. 43 Virttu Biologics Limited 44 Ascenta Therapeutics, Inc. 45 Onconova Therapeutics, Inc. 46 Genexine, Inc. 47 Viventia Biotechnologies Inc. 48 Oncovir, Inc. 49 Gliknik, Inc. 50 Karyopharm Therapeutics, Inc. 51 Agonox 52 Tolero Pharmaceuticals, Inc. 53 AlphaMab Co., Ltd 54 SillaJen Co. Ltd. 55 Mirati Therapeutics Inc. 56 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Combination Products 58 Assessment by Target 59 Assessment by Mechanism of Action 64 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 74 cetuximab - Drug Profile 74 Leukocyte Interleukin - Drug Profile 81 afatinib - Drug Profile 84 nimotuzumab - Drug Profile 87 nimorazole - Drug Profile 90 dalantercept - Drug Profile 92 SPC-2968 - Drug Profile 94 pemetrexed disodium - Drug Profile 96 everolimus - Drug Profile 102 rigosertib sodium - Drug Profile 106 oportuzumab monatox - Drug Profile 110 buparlisib hydrochloride - Drug Profile 112 Cell Therapy for Oncology - Drug Profile 116 pazopanib hydrochloride - Drug Profile 118 LY-2801653 - Drug Profile 123 selinexor - Drug Profile 124 GL-0817 - Drug Profile 127 Poly-ICLC - Drug Profile 128 golvatinib - Drug Profile 130 AT-406 - Drug Profile 132 Antisense Oligonucleotide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 135 GSK-2636771 - Drug Profile 136 S-488210 - Drug Profile 137 LJM-716 - Drug Profile 138 MGCD-265 - Drug Profile 140 pexastimogene devacirepvec - Drug Profile 142 JX-929 - Drug Profile 144 HF-10 - Drug Profile 145 MGCD-516 - Drug Profile 146 NBTXR-3 - Drug Profile 147 IC-1001 - Drug Profile 149 imgatuzumab - Drug Profile 150 urelumab - Drug Profile 152 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 154 LY-2606368 - Drug Profile 156 MV-NIS - Drug Profile 157 LGK-974 - Drug Profile 159 INC-280 - Drug Profile 160 GC-4419 - Drug Profile 162 HSV-1716 - Drug Profile 163 interleukin-15 - Drug Profile 165 MTL-005 - Drug Profile 166 IMGN-289 - Drug Profile 168 Cell Therapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 169 Gene Therapy to Activate p53 for Oncology - Drug Profile 170 GSK-2849330 - Drug Profile 171 GX-051 - Drug Profile 172 DTP-348 - Drug Profile 173 MEDI-6383 - Drug Profile 175 cetuximab biosimilar - Drug Profile 176 Monoclonal Antibody to Target CD147 for Pancreatic Cancer and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 177 cetuximab biosimilar - Drug Profile 179 Small Molecules to Inhibit 30S RNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile 180 Antibody to Inhibit FRMD4A for Oncology - Drug Profile 181 Monoclonal Antibody for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 182 cetuximab biosimilar - Drug Profile 183 cetuximab biosimilar - Drug Profile 184 KGP-94 - Drug Profile 185 Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 186 RNAi Oligonucleotide to Inhibit Casein Kinase 2 for Cancer - Drug Profile 187 Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 189 SHetA-2 - Drug Profile 190 SGI-7079 - Drug Profile 191 Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 192 Small Molecules for Head and Neck Cancer - Drug Profile 193 Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 194 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 243 Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 244 Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 245 Featured News & Press Releases 245 Appendix 254 Methodology 254 Coverage 254 Secondary Research 254 Primary Research 254 Expert Panel Validation 254 Contact Us 255 Disclaimer 255
List of Tables Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 14 Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2014 28 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 29 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2014 32 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 33 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 34 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline plc, H2 2014 35 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2014 36 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2014 37 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2014 38 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2014 39 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Santaris Pharma A/S, H2 2014 40 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2014 41 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H2 2014 42 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2014 43 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2014 44 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2014 45 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Nanobiotix, H2 2014 46 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2014 47 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2014 48 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics, Inc., H2 2014 49 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2014 50 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2014 51 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Biotechnologies Inc., H2 2014 52 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H2 2014 53 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2014 54 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 55 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Agonox, H2 2014 56 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 57 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H2 2014 58 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 59 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2014 60 Assessment by Monotherapy Products, H2 2014 61 Assessment by Combination Products, H2 2014 62 Number of Products by Stage and Target, H2 2014 65 Number of Products by Stage and Mechanism of Action, H2 2014 70 Number of Products by Stage and Route of Administration, H2 2014 74 Number of Products by Stage and Molecule Type, H2 2014 77 Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 198 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2014 247 Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2014 248
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
